Peripheral Arterial DiseaseNCT06752954
The Effectiveness of Covered Stent Viabahn and Drug-coated Balloon for Complex Femoropopliteal Artery Lesions
An observational study of Peripheral Arterial Disease, run by First Affiliated Hospital of Jinan University.
Trial summary
The purpose of this study is to evaluate the effectiveness of the covered stent Viabahn in treating long de novo femoropopliteal lesions (stenosis ≥ 25 cm, total occlusion ≥ 15 cm) or in-stent restenosis compared to drug-coated balloons (DCB) with or without a bailout bare nitinol stent. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peripheral Arterial Disease
- What is being tested?
- Viabahn endoprosthesis group and Drug-coated balloon group
- Type of treatment
- Medical device
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 25 Dec 2024to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 1. The patient is ≥ 18 years old. 2. Patient understands the nature of the procedure and provides written informed consent before enrolment in the study 3. The patient is willing to comply with specified follow-up evaluations at the specified times. 4. The patient presented a score from 2 to 5 following Rutherford classification. 5. The patient has a projected life expectancy of at least 24 months 6. Subject has a de novo or restenotic lesion with ≥ 70% stenosis in femoropopliteal artery, and for de novo lesion, the total lesion length ≥ 25cm, or chronic total occlusion (CTO) length ≥15cm.
Who may be able to join
- The patient is ≥ 18 years old.
- Patient understands the nature of the procedure and provides written informed consent before enrolment in the study
- The patient is willing to comply with specified follow-up evaluations at the specified times.
- The patient presented a score from 2 to 5 following Rutherford classification.
- The patient has a projected life expectancy of at least 24 months
- Subject has a de novo or restenotic lesion with ≥ 70% stenosis in femoropopliteal artery, and for de novo lesion, the total lesion length ≥ 25cm, or chronic total occlusion (CTO) length ≥15cm.
Who cannot join
- Patients with known hypersensitivity or contraindication to any of the following medications: Contrast media, Nitinol-titanium, antiplatelet therapy, anticoagulants, or thrombolytics therapy
- Pregnant women or Female patients with potential childbearing
- Patients who exhibit acute intraluminal thrombus at the target lesion vessel
- Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy
- The patient is currently participating in another investigational drug or device study that interferes with the study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparison of the Effectiveness of Viabahn® Vs. Drug-Coated Balloon With/without Bail-Out Bare Metal Stent in Treating Complicated Femoropopliteal Lesions
The purpose of this study is to evaluate the effectiveness of the covered stent Viabahn in treating long de novo femoropopliteal lesions (stenosis ≥ 25 cm, total occlusion ≥ 15 cm) or in-stent restenosis compared to drug-coated balloons (DCB) with or without a bailout bare nitinol stent.
Read the detailed description
This is a multicenter, observational prospective cohort clinical trial with clinical and image follow-up for two years post-procedure. Approximately 200 subjects will be enrolled into a Viabahn group (observe arm) or drug-coated balloons (DCB) group (contrast arm); Each group will include 100 patients.
All enrolled patients will be followed up for 12 and 24 months to assess the incidence of restenosis by duplex ultrasound and major adverse events. Follow-up visits occur at 12 and 24 months, as well as telephone visits after 1, 3,6 and 9 months.
- Conditions
- Peripheral Arterial Disease
- Being tested
- Viabahn endoprosthesis group, Drug-coated balloon group
- Keywords
- Viabahn endoprosthesis, Drug-coated balloon
- Medical subject headings
- Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Viabahn endoprosthesis groupDevice
Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
Drug-coated balloon groupDevice
Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
| Study group | Role | What they receive |
|---|---|---|
| Viabahn endoprosthesis group | Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis. Receives: Device: Viabahn endoprosthesis group | |
| Drug-coated balloon group | Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon. Receives: Device: Drug-coated balloon group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary patency
Peak systolic velocity ratio (PSVR ≤2.4) without any repeat intervention.
Measured: 12-month
Freedom from a composite of Major adverse events (MAEs)
Freedom from MAEs is defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major amputation, and all-cause of death
Measured: 12-month
Secondary outcomes (7)
Procedural success
Procedural success is defined as technical or device success without major adverse events during the hospital stay.
Measured: Immediately after interventional surgery
Primary assisted patency
Primary assisted patency is defined as maintaining patency in the target vessel after a repeat intervention to regain patency prior to complete occlusion.
Measured: 12-month
Secondary patency
Secondary patency is defined as maintaining patency in the target vessel after a repeat intervention to correct complete occlusion in the treated arterial segment.
Measured: 12-month
Clinically-driven target vessel revascularization (CD-TVR)
clinically-driven target vessel revascularization (CD-TVR) is defined as repeat intervention performed during enrollment in the clinical study.
Measured: 12-month
Primary sustained clinical improvement
Defined as a sustained upward shift of at least one category on the Rutherford classification without the need for repeated target lesion revascularization (TLR) in surviving patients.
Measured: 12-month
Secondary sustained clinical improvement
Defined as a sustained upward shift of at least one category on the Rutherford classification3, including the need for repeated target lesion revascularization (TLR) in surviving patients.
Measured: 12-month
Vasc quality of life score
Change of Vasc quality of life score
Measured: 12-month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2024
- Study start25 Dec 2024 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Jinan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chengzhi Li, First Affiliated Hospital of Jinan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06752954
- Sponsor's protocol ID
- The support study
- Status last verified
- Nov 2024
- First submitted
- 22 Dec 2024
- Last updated
- 31 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Effectiveness of Viabahn® Vs. Drug-Coated Balloon With/without Bail-Out Bare Metal Stent in Treating Complicated Femoropopliteal Lesions
- ClinicalTrials.gov ID
- NCT06752954
- Acronym / sponsor ID
- The support study
- Conditions
- Peripheral Arterial Disease
- Keywords
- Viabahn endoprosthesis, Drug-coated balloon
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Jinan UniversityUniversity, hospital or other
- Study start
- 25 Dec 2024 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 31 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness of the covered stent Viabahn in treating long de novo femoropopliteal lesions (stenosis ≥ 25 cm, total occlusion ≥ 15 cm) or in-stent restenosis compared to drug-coated balloons (DCB) with or without a bailout bare nitinol stent.
Detailed description
This is a multicenter, observational prospective cohort clinical trial with clinical and image follow-up for two years post-procedure. Approximately 200 subjects will be enrolled into a Viabahn group (observe arm) or drug-coated balloons (DCB) group (contrast arm); Each group will include 100 patients.
All enrolled patients will be followed up for 12 and 24 months to assess the incidence of restenosis by duplex ultrasound and major adverse events. Follow-up visits occur at 12 and 24 months, as well as telephone visits after 1, 3,6 and 9 months.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Viabahn endoprosthesis group | – | Device: Viabahn endoprosthesis groupPatients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis. |
| Drug-coated balloon group | – | Device: Drug-coated balloon groupPatients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 1. The patient is ≥ 18 years old. 2. Patient understands the nature of the procedure and provides written informed consent before enrolment in the study 3. The patient is willing to comply with specified follow-up evaluations at the specified times. 4. The patient presented a score from 2 to 5 following Rutherford classification. 5. The patient has a projected life expectancy of at least 24 months 6. Subject has a de novo or restenotic lesion with ≥ 70% stenosis in femoropopliteal artery, and for de novo lesion, the total lesion length ≥ 25cm, or chronic total occlusion (CTO) length ≥15cm.
Key inclusion criteria (6 listed)
- The patient is ≥ 18 years old.
- Patient understands the nature of the procedure and provides written informed consent before enrolment in the study
- The patient is willing to comply with specified follow-up evaluations at the specified times.
- The patient presented a score from 2 to 5 following Rutherford classification.
- The patient has a projected life expectancy of at least 24 months
Key exclusion criteria (5 listed)
- Patients with known hypersensitivity or contraindication to any of the following medications: Contrast media, Nitinol-titanium, antiplatelet therapy, anticoagulants, or thrombolytics therapy
- Pregnant women or Female patients with potential childbearing
- Patients who exhibit acute intraluminal thrombus at the target lesion vessel
- Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy
- The patient is currently participating in another investigational drug or device study that interferes with the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Viabahn endoprosthesis groupViabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis. | Device | Viabahn endoprosthesis group |
| Drug-coated balloon groupPatients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon. | Device | Drug-coated balloon group |
Primary outcome
Primary patency
Time frame: 12-month
Peak systolic velocity ratio (PSVR ≤2.4) without any repeat intervention.
Freedom from a composite of Major adverse events (MAEs)
Time frame: 12-month
Freedom from MAEs is defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major amputation, and all-cause of death
7 secondary outcomes
Procedural success
Time frame: Immediately after interventional surgery
Primary assisted patency
Time frame: 12-month
Secondary patency
Time frame: 12-month
Clinically-driven target vessel revascularization (CD-TVR)
Time frame: 12-month
Primary sustained clinical improvement
Time frame: 12-month
Secondary sustained clinical improvement
Time frame: 12-month
Vasc quality of life score
Time frame: 12-month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2024.
Related trials for Peripheral Arterial Disease
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Active, not recruiting
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
Thrombosis, Arterial Occlusive Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Peripheral Arterial Disease, run by First Affiliated Hospital of Jinan University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiandong Guo (+8613420187264, 407939203@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary patency (time frame: 12-month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2024; AzTrials last refreshed its copy on 8 Nov 2026.